WHAT IS CLAIMED IS:

1. A pharmaceutical composite capsule formulation comprising:
   1) an independent irbesartan unit comprising irbesartan or a pharmaceutically acceptable salt thereof; and
   2) an independent HMG-CoA reductase inhibitor unit comprising an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, and an alkaline additive,
   wherein the independent irbesartan unit and the independent HMG-CoA reductase inhibitor unit ~~said independent units~~ are separated from each other within the ~~a~~ capsule;
   wherein the independent irbesartan unit and the independent HMG-CoA reductase inhibitor unit are each in a granule or tablet form;
   wherein at least one of the independent irbesartan unit and the independent HMG-CoA reductase inhibitor unit takes a tablet form which has a diameter of 3 mm or less and a thickness of 3 mm or less.

2. The pharmaceutical composite capsule formulation of claim 1, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of rosuvastatin, lovastatin, atorvastatin, pravastatin, fluvastatin, pitavastatin, simvastatin, rivastatin, cerivastatin, velostatin, mevastatin, a pharmaceutically acceptable salt thereof, a precursor thereof and a mixture thereof.

3. The pharmaceutical composite capsule formulation of claim 2, wherein the HMG-CoA reductase inhibitor is atorvastatin calcium.

~~4. The pharmaceutical composite capsule formulation of claim 1, wherein the independent irbesartan unit and the independent HMG-CoA reductase inhibitor unit are each in a granule or tablet form.~~

~~5. The pharmaceutical composite capsule formulation of claim 4, wherein at least one of the independent irbesartan unit and the independent HMG-CoA reductase inhibitor unit takes a tablet form.~~

~~6. The pharmaceutical composite capsule formulation of claim 4, wherein the tablet has a diameter of 3 mm or less.~~

~~7. The pharmaceutical composite capsule formulation of claim 4, wherein the tablet has a thickness of 3 mm or less.~~

4~~8~~. The pharmaceutical composite capsule formulation of claim 1~~4~~, wherein the tablet further comprises a coating layer.

5~~9~~. The pharmaceutical composite capsule formulation of claim 4~~8~~, wherein the coating layer is made of a coating material selected from the group consisting of methyl cellulose,

ethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, hydroxyethyl cellulose, hydroxypropyl methyl cellulose and a mixture thereof.

610. The pharmaceutical composite capsule formulation of claim 59, wherein the coating material is employed in an amount of from 1 to 20 wt%, based on the total weight of the tablet.

711. The pharmaceutical composite capsule formulation of claim 1, wherein the capsule is a hard capsule.

812. The pharmaceutical composite capsule formulation of claim 711, wherein the capsule is made of a material selected from the group consisting of hypromellose, pullulan, gelatin and polyvinyl alcohol.

913. The pharmaceutical composite capsule formulation of claim 1, wherein the alkaline additive is selected from the group consisting of $NaHCO_3$, $CaCO_3$, $MgCO_3$, KH_2PO_4, K_2HPO_3, calcium phosphate tribasic, arginine, lysine, histidine, meglumine, aluminum magnesium silicate, aluminum magnesium metasilicate, a salt thereof and a mixture thereof.

1014. The pharmaceutical composite capsule formulation of claim 913, wherein the alkaline additive is $NaHCO_3$, $MgCO_3$, or a mixture thereof.

1115. The pharmaceutical composite capsule formulation of claim 1, wherein the alkaline additive is used in an amount of from 2 to 10 parts by weight, based on 1 part by weight of the HMG-CoA reductase inhibitor.

1216. The pharmaceutical composite capsule formulation of claim 1, wherein the independent irbesartan unit further comprises a pharmaceutically acceptable additive selected from the group consisting of a binder, a disintegrant, a lubricant, a diluent, a colorant, an anti-tackifier, a surfactant and a mixture thereof.

1317. The pharmaceutical composite capsule formulation of claim 1, comprising irbesartan or the pharmaceutically acceptable salt thereof in an amount of from 8 mg to 600 mg per unit formulation.

1418. The pharmaceutical composite capsule formulation of claim 1, comprising the HMG-

CoA reductase inhibitor or the pharmaceutically acceptable salt thereof in an amount of from 5 mg to 80 mg per unit formulation.

1519. The pharmaceutical composite capsule formulation of claim 1, wherein the irbesartan and the HMG-CoA reductase inhibitor are individually released at a rate of 80% or higher within 30 min.

1620. The pharmaceutical composite capsule formulation of claim 159, wherein the irbesartan and the HMG-CoA reductase inhibitor are individually released at a rate of 80% or higher within 15 min.

1721. The pharmaceutical composite capsule formulation of claim 1 for use in therapy.

1822. A method for preparing the pharmaceutical composite capsule formulation of claim 1, comprising:

1) forming irbesartan granules or tablets comprising irbesartan or a pharmaceutically acceptable salt thereof;

2) forming HMG-CoA reductase inhibitor granules or tablets comprising an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, and an alkaline additive;

3) loading the irbesartan granules or tablets of step 1) and the HMG-CoA reductase inhibitor granules or tablets of step 2) into a hard capsule, such that said irbesartan granules or tablets are separated from said HMG-CoA reductase inhibitor granules or tablets within the capsule,

wherein at least one of the irbesartan or the pharmaceutically acceptable salt thereof in step 1) and the HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof in step 2) is formed into tablets, which has a diameter of 3 mm or less and a thickness of 3 mm or less.

~~23. The method of claim 22, wherein at least one of the irbesartan or the pharmaceutically acceptable salt thereof in step 1) and the HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof in step 2) is formed into tablets.~~

1924. The method of claim 1823, further comprising coating the tablets.

WHAT IS CLAIMED IS:

1. A pharmaceutical composite capsule formulation comprising:
   1) an independent irbesartan unit comprising irbesartan or a pharmaceutically acceptable salt thereof; and
   2) an independent HMG-CoA reductase inhibitor unit comprising an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, and an alkaline additive,
   wherein the independent irbesartan unit and the independent HMG-CoA reductase inhibitor unit are separated from each other within the capsule;
   wherein the independent irbesartan unit and the independent HMG-CoA reductase inhibitor unit are each in a granule or tablet form;
   wherein at least one of the independent irbesartan unit and the independent HMG-CoA reductase inhibitor unit takes a tablet form which has a diameter of 3 mm or less and a thickness of 3 mm or less.

2. The pharmaceutical composite capsule formulation of claim 1, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of rosuvastatin, lovastatin, atorvastatin, pravastatin, fluvastatin, pitavastatin, simvastatin, rivastatin, cerivastatin, velostatin, mevastatin, a pharmaceutically acceptable salt thereof, a precursor thereof and a mixture thereof.

3. The pharmaceutical composite capsule formulation of claim 2, wherein the HMG-CoA reductase inhibitor is atorvastatin calcium.

4. The pharmaceutical composite capsule formulation of claim 1, wherein the tablet further comprises a coating layer.

5. The pharmaceutical composite capsule formulation of claim 4, wherein the coating layer is made of a coating material selected from the group consisting of methyl cellulose, ethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, hydroxyethyl cellulose, hydroxypropyl methyl cellulose and a mixture thereof.

6. The pharmaceutical composite capsule formulation of claim 5, wherein the coating material is employed in an amount of from 1 to 20 wt%, based on the total weight of the tablet.

7. The pharmaceutical composite capsule formulation of claim 1, wherein the capsule is a hard capsule.

8. The pharmaceutical composite capsule formulation of claim 7, wherein the capsule is made of a material selected from the group consisting of hypromellose, pullulan, gelatin and polyvinyl alcohol.

9. The pharmaceutical composite capsule formulation of claim 1, wherein the alkaline additive is selected from the group consisting of $NaHCO_3$, $CaCO_3$, $MgCO_3$, KH_2PO_4, K_2HPO_3, calcium phosphate tribasic, arginine, lysine, histidine, meglumine, aluminum magnesium silicate, aluminum magnesium metasilicate, a salt thereof and a mixture thereof.

10. The pharmaceutical composite capsule formulation of claim 9, wherein the alkaline additive is $NaHCO_3$, $MgCO_3$, or a mixture thereof.

11. The pharmaceutical composite capsule formulation of claim 1, wherein the alkaline additive is used in an amount of from 2 to 10 parts by weight, based on 1 part by weight of the HMG-CoA reductase inhibitor.

12. The pharmaceutical composite capsule formulation of claim 1, wherein the independent irbesartan unit further comprises a pharmaceutically acceptable additive selected from the group consisting of a binder, a disintegrant, a lubricant, a diluent, a colorant, an anti-tackifier, a surfactant and a mixture thereof.

13. The pharmaceutical composite capsule formulation of claim 1, comprising irbesartan or the pharmaceutically acceptable salt thereof in an amount of from 8 mg to 600 mg per unit formulation.

14. The pharmaceutical composite capsule formulation of claim 1, comprising the HMG-CoA reductase inhibitor or the pharmaceutically acceptable salt thereof in an amount of from 5 mg to 80 mg per unit formulation.

15. The pharmaceutical composite capsule formulation of claim 1, wherein the irbesartan and the HMG-CoA reductase inhibitor are individually released at a rate of 80% or higher within 30 min.

16. The pharmaceutical composite capsule formulation of claim 15, wherein the irbesartan and the HMG-CoA reductase inhibitor are individually released at a rate of 80% or higher within 15 min.

17. The pharmaceutical composite capsule formulation of claim 1 for use in therapy.

18. A method for preparing the pharmaceutical composite capsule formulation of claim 1, comprising:
    1) forming irbesartan granules or tablets comprising irbesartan or a pharmaceutically acceptable salt thereof;
    2) forming HMG-CoA reductase inhibitor granules or tablets comprising an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, and an alkaline additive;
    3) loading the irbesartan granules or tablets of step 1) and the HMG-CoA reductase

inhibitor granules or tablets of step 2) into a hard capsule, such that said irbesartan granules or tablets are separated from said HMG-CoA reductase inhibitor granules or tablets within the capsule,
wherein at least one of the irbesartan or the pharmaceutically acceptable salt thereof in step 1) and the HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof in step 2) is formed into tablets, which has a diameter of 3 mm or less and a thickness of 3 mm or less.

19. The method of claim 18, further comprising coating the tablets.